Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Whole Genome Sequencing Prioritizes CHEK2, EWSR1, and TIAM1 as Possible Predisposition Genes for Familial Non-Medullary Thyroid Cancer

A. Srivastava, S. Giangiobbe, D. Skopelitou, B. Miao, N. Paramasivam, C. Diquigiovanni, E. Bonora, K. Hemminki, A. Försti, OR. Bandapalli

. 2021 ; 12 (-) : 600682. [pub] 20210222

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012526

Familial inheritance in non-medullary thyroid cancer (NMTC) is an area that has yet to be adequately explored. Despite evidence suggesting strong familial clustering of non-syndromic NMTC, known variants still account for a very small percentage of the genetic burden. In a recent whole genome sequencing (WGS) study of five families with several NMTCs, we shortlisted promising variants with the help of our in-house developed Familial Cancer Variant Prioritization Pipeline (FCVPPv2). Here, we report potentially disease-causing variants in checkpoint kinase 2 (CHEK2), Ewing sarcoma breakpoint region 1 (EWSR1) and T-lymphoma invasion and metastasis-inducing protein 1 (TIAM1) in one family. Performing WGS on three cases, one probable case and one healthy individual in a family with familial NMTC left us with 112254 variants with a minor allele frequency of less than 0.1%, which was reduced by pedigree-based filtering to 6368. Application of the pipeline led to the prioritization of seven coding and nine non-coding variants from this family. The variant identified in CHEK2, a known tumor suppressor gene involved in DNA damage-induced DNA repair, cell cycle arrest, and apoptosis, has been previously identified as a germline variant in breast and prostate cancer and has been functionally validated by Roeb et al. in a yeast-based assay to have an intermediate effect on protein function. We thus hypothesized that this family may harbor additional disease-causing variants in other functionally related genes. We evaluated two further variants in EWSR1 and TIAM1 with promising in silico results and reported interaction in the DNA-damage repair pathway. Hence, we propose a polygenic mode of inheritance in this family. As familial NMTC is considered to be more aggressive than its sporadic counterpart, it is important to identify such susceptibility genes and their associated pathways. In this way, the advancement of personalized medicine in NMTC patients can be fostered. We also wish to reopen the discussion on monogenic vs polygenic inheritance in NMTC and instigate further development in this area of research.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012526
003      
CZ-PrNML
005      
20220506130832.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fendo.2021.600682 $2 doi
035    __
$a (PubMed)33692755
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Srivastava, Aayushi $u Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany $u Preclinical Pediatric Oncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany $u Medical Faculty, Heidelberg University, Heidelberg, Germany
245    10
$a Whole Genome Sequencing Prioritizes CHEK2, EWSR1, and TIAM1 as Possible Predisposition Genes for Familial Non-Medullary Thyroid Cancer / $c A. Srivastava, S. Giangiobbe, D. Skopelitou, B. Miao, N. Paramasivam, C. Diquigiovanni, E. Bonora, K. Hemminki, A. Försti, OR. Bandapalli
520    9_
$a Familial inheritance in non-medullary thyroid cancer (NMTC) is an area that has yet to be adequately explored. Despite evidence suggesting strong familial clustering of non-syndromic NMTC, known variants still account for a very small percentage of the genetic burden. In a recent whole genome sequencing (WGS) study of five families with several NMTCs, we shortlisted promising variants with the help of our in-house developed Familial Cancer Variant Prioritization Pipeline (FCVPPv2). Here, we report potentially disease-causing variants in checkpoint kinase 2 (CHEK2), Ewing sarcoma breakpoint region 1 (EWSR1) and T-lymphoma invasion and metastasis-inducing protein 1 (TIAM1) in one family. Performing WGS on three cases, one probable case and one healthy individual in a family with familial NMTC left us with 112254 variants with a minor allele frequency of less than 0.1%, which was reduced by pedigree-based filtering to 6368. Application of the pipeline led to the prioritization of seven coding and nine non-coding variants from this family. The variant identified in CHEK2, a known tumor suppressor gene involved in DNA damage-induced DNA repair, cell cycle arrest, and apoptosis, has been previously identified as a germline variant in breast and prostate cancer and has been functionally validated by Roeb et al. in a yeast-based assay to have an intermediate effect on protein function. We thus hypothesized that this family may harbor additional disease-causing variants in other functionally related genes. We evaluated two further variants in EWSR1 and TIAM1 with promising in silico results and reported interaction in the DNA-damage repair pathway. Hence, we propose a polygenic mode of inheritance in this family. As familial NMTC is considered to be more aggressive than its sporadic counterpart, it is important to identify such susceptibility genes and their associated pathways. In this way, the advancement of personalized medicine in NMTC patients can be fostered. We also wish to reopen the discussion on monogenic vs polygenic inheritance in NMTC and instigate further development in this area of research.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a checkpoint kinasa 2 $x chemie $x genetika $x metabolismus $7 D064447
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a genom lidský $7 D015894
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a rodokmen $7 D010375
650    _2
$a protein EWS vázající RNA $x chemie $x genetika $x metabolismus $7 D034802
650    _2
$a sekvenční seřazení $7 D016415
650    _2
$a protein TIAM1 $x chemie $x genetika $x metabolismus $7 D000075684
650    _2
$a papilární karcinom štítné žlázy $x genetika $x metabolismus $7 D000077273
650    _2
$a sekvenování celého genomu $7 D000073336
651    _2
$a Itálie $7 D007558
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Giangiobbe, Sara $u Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany $u Medical Faculty, Heidelberg University, Heidelberg, Germany
700    1_
$a Skopelitou, Diamanto $u Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany $u Preclinical Pediatric Oncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany $u Medical Faculty, Heidelberg University, Heidelberg, Germany
700    1_
$a Miao, Beiping $u Preclinical Pediatric Oncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Paramasivam, Nagarajan $u Computational Oncology, National Center for Tumor Diseases (NCT), Molecular Diagnostics Program, Heidelberg, Germany
700    1_
$a Diquigiovanni, Chiara $u Unit of Medical Genetics, Department of Medical and Surgical Sciences, S. Orsola-Malphigi Hospital, University of Bologna, Bologna, Italy
700    1_
$a Bonora, Elena $u Unit of Medical Genetics, Department of Medical and Surgical Sciences, S. Orsola-Malphigi Hospital, University of Bologna, Bologna, Italy
700    1_
$a Hemminki, Kari $u Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany $u Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czechia
700    1_
$a Försti, Asta $u Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany $u Preclinical Pediatric Oncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Bandapalli, Obul Reddy $u Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany $u Preclinical Pediatric Oncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany $u Medical Faculty, Heidelberg University, Heidelberg, Germany
773    0_
$w MED00174543 $t Frontiers in endocrinology $x 1664-2392 $g Roč. 12, č. - (2021), s. 600682
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33692755 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130824 $b ABA008
999    __
$a ok $b bmc $g 1789927 $s 1163727
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c - $d 600682 $e 20210222 $i 1664-2392 $m Frontiers in endocrinology $n Front. endocrinol. $x MED00174543
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...